Evidence map›Paper›PMID 29651598›Full record

Trial reportLung2018

Geriatric Assessment for Older Patients with Non-small Cell Lung Cancer: Daily Practice of Centers Participating in the NVALT25-ELDAPT Trial.

Elisabeth J M Driessen, Judith G M van Loon, Huub A Maas, Anne-Marie C Dingemans, Maryska L G Janssen-Heijnen

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Lung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02284308 (ELDAPT), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02284308 active not recruitingnot on this map

ELDAPT: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the oPtimal Treatment Strategy

TypeobservationalSponsorMaastricht Radiation OncologyRan2016 to 2029Enrolled180ConditionsNSCLC
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elisabeth J M DriessenDepartment of Clinical Epidemiology, VieCuri Medical Center, P.O. box 1926, 5900 BX, Venlo, The Netherlands. ldriessen@viecuri.nl.
Judith G M van LoonMAASTRO Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. box 3035, 6202 NA, Maastricht, The Netherlands.
Huub A MaasDepartment of Geriatric Medicine, Elisabeth-Tweesteden Hospital, Hilvarenbeekseweg 60, 5022 GC, Tilburg, The Netherlands.
Anne-Marie C DingemansDepartment of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.
Maryska L G Janssen-HeijnenDepartment of Clinical Epidemiology, VieCuri Medical Center, P.O. box 1926, 5900 BX, Venlo, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGeriatric assessment (GA) for older patients with lung cancer could provide insight into vulnerability, cognitive impairment, and risk of toxicity. Discontinuation and complications of intensive treatment could potentially be prevented in vulnerable and frail patients. This study aimed to evaluate current clinical practice of GA for older patients with lung cancer in the Netherlands and identify potential hurdles for implementation.

methodsPulmonologists and radiation oncologists participating in the NVALT25-ELDAPT trial completed an online questionnaire regarding current practice of GA, added value of GA for treatment decision-making and logistic barriers for patients with non-small cell lung cancer.

results15 out of 17 centers responded. Three performed GA as standard procedure, three on indication, eight considered a frailty screening step before GA, and one did not perform GA. Suspicion of cognitive problems was mentioned most often as indication for GA and of added value for treatment decision-making, followed by older age, curative-intent treatment, and stage I-III lung cancer. Administered instruments for screening and extensive GA were diverse. Main barriers to implement GA in clinical practice were logistic problems (timescales and availability of trained personnel).

conclusionThe use of GA in clinical practice for patients with lung cancer varied widely across centers regarding instruments and domains. Physicians are uniform in their opinion about indications for GA and the added value for treatment decision-making. Research should focus on manageable instruments and important domains to assess for this heterogeneous group of older patients with lung cancer to optimize treatment selection. Trial registration The NVALT25-ELDAPT trial is registered under trial number NCT02284308. Details are available at http://www.eldapt.org (predominantly in Dutch).

Indexed as

Surveys and QuestionnairesAgedAge FactorsCarcinoma, Non-Small-Cell LungClinical Decision-MakingFemaleFrail ElderlyFrailtyGeriatric AssessmentHumansLung NeoplasmsMaleMiddle AgedNetherlandsPatient SelectionPractice Patterns, Physicians'ElderlyFrailtyGeriatric assessmentNon-small cell lung cancerQuestionnaire

Identifiers

PMID29651598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.